Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy
Authors:
- 31 December 2008
- journal article
- Published by Elsevier in Nanomedicine: Nanotechnology, Biology and Medicine
- Vol. 4 (4) , 295-301
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Pituitary Tumor-Transforming 1 Increases Cell Motility and Promotes Lymph Node Metastasis in Esophageal Squamous Cell CarcinomaCancer Research, 2008
- Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragmentGynecologic Oncology, 2007
- Control of human mesothelin-expressing tumors by DNA vaccinesGene Therapy, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- A DNA vaccine encoding a single-chain trimer of HLA-A2 linked to human mesothelin peptide generates anti-tumor effects against human mesothelin-expressing tumorsVaccine, 2007
- Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic MarkerCancer Epidemiology, Biomarkers & Prevention, 2006
- Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensorCancer Detection Prevention, 2006
- Expression of novel markers of pancreatic ductal adenocarcinoma in pancreatic nonductal neoplasms: additional evidence of different genetic pathwaysLaboratory Investigation, 2005
- Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer PatientsJournal of Experimental Medicine, 2004
- In vivo cancer targeting and imaging with semiconductor quantum dotsNature Biotechnology, 2004